Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1975 Jan;53(1):121–125. doi: 10.1111/j.1476-5381.1975.tb07338.x

Inhibition of 5-hydroxytryptamine-induced human blood platelet aggregation by chlorpromazine and its metabolites.

D J Boullin, D G Grahame-Smith, R P Grimes, H F Woods
PMCID: PMC1666266  PMID: 1125484

Abstract

1 Blood platelets from normal human subjects were isolated and aggregated in vitro with adenosine diphosphate (ADP) or 5-hydroxytryptamine (5-HT). 2 The effects of chlorpromazine and 7 major metabolites upon 5-HT-induced aggregation were investigated. 3 All the phenothiazines inhibited 5-HT-induced aggregation when added to platelet rich plasma 3 min prior to 5-HT. 4 There were no qualitative differences in the inhibitory effects, but inhibitory potency varied over a wide range. The decreasing order of potency was monodesmethylchlorpromazine, chlorpromazine, 7-hydroxychlorpromazine, didesmethylchlorpromazine, 3,7 -dimethoxy-chlorpromazine, didesmethylchlorpromazine sulphoxide, chlorpromazine sulphoxide, chlorpromazine nitroxide.

Full text

PDF
121

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ahtee L. 5-Hydroxytryptamine release from blood platelets and haemolysis of red blood cells of rabbit induced by phenothiazines and related compounds. Ann Med Exp Biol Fenn. 1966;44(3):431–452. [PubMed] [Google Scholar]
  2. Ahtee L., Mattila M. J., Vapaatalo H. I. The binding of some phenothiazines to human serum in vitro. Biochem Pharmacol. 1967 Dec;16(12):2432–2435. doi: 10.1016/0006-2952(67)90229-8. [DOI] [PubMed] [Google Scholar]
  3. Ahtee L., Paasonen M. K. Distribution of some phenothiazines in red blood cells and platelets. J Pharm Pharmacol. 1966 Feb;18(2):126–128. doi: 10.1111/j.2042-7158.1966.tb07834.x. [DOI] [PubMed] [Google Scholar]
  4. Ahtee L., Paasonen M. K. The haemolytic effect of some phenothiazine derivatives. Ann Med Exp Biol Fenn. 1965;43(2):101–105. [PubMed] [Google Scholar]
  5. Ahtee L. Surface activity of phenothiazines and related compounds. Ann Med Exp Biol Fenn. 1966;44(3):453–457. [PubMed] [Google Scholar]
  6. BARTHOLINI G., PLETSCHER A., GEY K. F. Diminution of 5-hydroxytryptamine in thrombocytes in vitro by chlorpromazine and related compounds. Experientia. 1961 Dec 15;17:541–542. doi: 10.1007/BF02156407. [DOI] [PubMed] [Google Scholar]
  7. Baumgartner H. R., Born G. V. Effects of 5-hydroxytryptamine on platelet aggregation. Nature. 1968 Apr 13;218(5137):137–141. doi: 10.1038/218137a0. [DOI] [PubMed] [Google Scholar]
  8. Boullin D. J., Green A. R., Price K. S. The mechanism of adenosine diphosphate induced platelet aggregation: binding to platelet receptors and inhibition of binding and aggregation by prostaglandin E 1 . J Physiol. 1972 Mar;221(2):415–426. doi: 10.1113/jphysiol.1972.sp009758. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Curry S. H. Chlorpromazine: concentrations in plasma, excretion in urine and duration of effect. Proc R Soc Med. 1971 Mar;64(3):285–289. doi: 10.1177/003591577106400323. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Curry S. H., Lader M. H., Mould G. P., Sakalis G. Proceedings: Clinical pharmacology of chlorpromazine. Br J Pharmacol. 1972 Feb;44(2):370P–371P. [PMC free article] [PubMed] [Google Scholar]
  11. Manian A. A., Efron D. H., Goldberg M. E. A comparative pharmacological study of a series of monohydroxylated and methoxylated chlorpromazine derivatives. Life Sci. 1965 Dec;4(24):2425–2438. doi: 10.1016/0024-3205(65)90298-5. [DOI] [PubMed] [Google Scholar]
  12. Miller R. J., Iversen L. L. Effect of chlorpromazine and some of its metabolites on the dopamine-sensitive adenylate cyclase of rat brain striatum. J Pharm Pharmacol. 1974 Feb;26(2):142–144. doi: 10.1111/j.2042-7158.1974.tb09243.x. [DOI] [PubMed] [Google Scholar]
  13. O'BRIEN J. R. A COMPARISON OF PLATELET AGGREGATION PRODUCED BY SEVEN COMPOUNDS AND A COMPARISON OF THEIR INHIBITORS. J Clin Pathol. 1964 May;17:275–281. doi: 10.1136/jcp.17.3.275. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. POSNER H. S., HEARST E., TAYLOR W. L., COSMIDES G. J. Model metabolites of chlorpromazine and promazine: relative activities in some pharmacological and behavioral tests. J Pharmacol Exp Ther. 1962 Jul;137:84–90. [PubMed] [Google Scholar]
  15. Sakalis G., Chan T. L., Gershon S., Park S. The possible role of metabolites in therapeutic response to chlorpromazine treatment. Psychopharmacologia. 1973 Sep 28;32(3):279–284. doi: 10.1007/BF00422150. [DOI] [PubMed] [Google Scholar]
  16. Solatunituri E., Ahtee L. Subcellular distribution of some phenothiazines in blood platelets of rabbit. J Pharm Pharmacol. 1968 Apr;20(4):289–292. doi: 10.1111/j.2042-7158.1968.tb09740.x. [DOI] [PubMed] [Google Scholar]
  17. Telkkä A., Nyholm M., Paasonen M. K. Effect of chlorpromazine and reserpine on the blood platelets of rabbit. An electron microscope study. Experientia. 1964 Jan 15;20(1):27–28. doi: 10.1007/BF02146024. [DOI] [PubMed] [Google Scholar]
  18. Usdin E. The assay of chlorpromazine and metabolites in blood, urine, and other tissues. CRC Crit Rev Clin Lab Sci. 1971 Sep;2(3):347–391. doi: 10.3109/10408367109151312. [DOI] [PubMed] [Google Scholar]
  19. Vapaatalo H. I., Ahtee L., Paasonen M. K. Release of adrenaline and noradrenaline by some phenothiazines from the bovine adrenal gland. Ann Med Exp Biol Fenn. 1966;44(3):464–468. [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES